[ A20-74] Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V
Last updated 18.02.2021
Project no.:
A20-74
Commission:
Commission awarded on 28.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
| Solid tumours expressing an NTRK gene fusion, disease locally advanced or metastatic or where surgical resection is likely to result in severe morbidity: patients 12 years of age and older who have not received a prior NTRK inhibitor and who have no satisfactory treatment options |
Result of dossier assessment:
| Added benefit not proven due to lack of suitable study data |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-75 | Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-07 | Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74 | Commission completed |
| A24-78 | Entrectinib (solid tumours with a neurotrophic tyrosine receptor kinase [NTRK] gene fusion, > 1 month to < 12 years) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-02-18: A G-BA decision was published.